文献速递关节外科

减少金属对金属髋关节置换术后监测负担:基于大样本队列的风险适配三层模型

Reducing the Surveillance Burden in Metal-on-Metal Hip Arthroplasty: A Risk-Adapted Three-Tier Model Based on a Large Patient Cohort.
PubMed 文献 · J Arthroplasty · 2026-09-07

该研究基于845例金属对金属髋关节表面置换和大头全髋关节置换患者,开发风险适配随访路径。分层模型采用Tier 1≥3和Tier 2≥2阈值,敏感性0.84、特异性0.51、AUROC 0.67;

要点

  • Tier 1最强预测因素为女性(OR 2.0)、双侧植入(1.7)、GFR<60(1.6)。
  • Tier 2预测因素为X线异常(OR 10.6)、疼痛(3.7)、金属离子水平异常(2.5)。
  • 分层模型敏感性0.84、特异性0.51,优于MHRA方案的0.88和0.34。

核心结论

  • 提出风险适配三层路径:基线分层、高危每三年监测、仅Tier 2异常者行MRI。
  • 低危患者10年后除非有症状,否则随访获益有限。

研究设计与样本

  • 回顾性分析845例金属对金属髋关节表面置换和大头全髋关节置换患者。
  • 主要结局为异常MRI或翻修,采用逻辑回归识别预测因素并转化为临床风险评分。
  • 证据等级为Level II。

主要发现

  • Tier 1预测因素包括女性(OR 2.0)、双侧植入(1.7)、GFR<60(1.6)、年龄<50岁(1.4)、头尺寸<48mm(1.2)、高危植入物(1.2)。
  • Tier 2预测因素包括X线异常(OR 10.6)、疼痛(3.7)、金属离子水平异常(2.5)、其他症状(1.6)。
  • 分层模型阈值Tier 1≥3和Tier 2≥2时,敏感性0.84、特异性0.51、AUROC 0.67。
  • MHRA方案敏感性0.88、特异性0.34、AUROC 0.61。
  • 分层模型将年随访率从69%降至53%,高危复查延长至每三年,低危监测停止。

关键数值与推荐

  • Tier 1风险评分≥3分定义为高危,Tier 2风险评分≥2分定义为需进一步MRI评估。
  • 高危患者每三年进行症状评估、X线检查及可选金属离子检测。

临床怎么用

  • 采用Tier 1临床风险评分进行基线分层,识别高危和低危患者。
  • 高危患者每三年随访,包括症状、X线和可选金属离子检测。
  • 仅Tier 2评分≥2分的患者行MRI检查。
  • 低危患者10年后除非有症状,否则可限制随访。

局限性

  • 未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Since 2017, the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom has mandated comprehensive surveillance for patients who have metal-on-metal (MoM) hips. We aimed to develop a risk-adapted follow-up pathway to safely reduce unnecessary visits and investigations. METHODS: We analyzed 845 MoM hip resurfacings and large-head MoM total hip arthroplasties (THAs). The primary outcome was abnormal magnetic resonance imaging (MRI) or revision. Logistic regression identified predictors, which were translated into clinical risk scores for Tiers 1 and 2. RESULTS: In Tier 1, the strongest predictors (by adjusted odds ratio) were women (2.0), bilateral implants (1.7), glomerular filtration rate less than 60 (1.6), age less than 50 years (1.4), head size less than 48 mm (1.2), and high-risk implant (1.2). In Tier 2, predictors were abnormal x-ray (10.6), pain (3.7), abnormal metal-ion level (2.5), and other symptoms (1.6). The hierarchical model, using thresholds of Tier 1 ≥ 3 and Tier 2 ≥ 2, achieved a sensitivity of 0.84, specificity of 0.51, and area under the receiver operating characteristic curve (AUROC) of 0.67. By comparison, the MHRA approach demonstrated a sensitivity of 0.88, specificity of 0.34, and an AUROC of 0.61. The hierarchical model reduced the annual follow-up from 69 to 53%. High-risk reviews were extended to every three years, and low-risk surveillance was discontinued. This resulted in savings of £46,000 to £59,000 ($61,400 to $78,800) per 1,000 patients annually, a 75% reduction in workload versus the MHRA approach. CONCLUSIONS: We propose a risk-adapted, three-tier pathway: (1) baseline stratification into high- and low-risk groups using the clinical risk score; (2) surveillance of high-risk patients every three years, including symptom review, radiographs, and optional metal-ion testing; and (3) MRI reserved for patients who have Tier 2 abnormalities above the risk score. Low-risk patients have limited benefits from follow-up beyond 10 years unless they are symptomatic. LEVEL OF EVIDENCE: Level II.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Selim A, Saeed A, George A, et al. Reducing the Surveillance Burden in Metal-on-Metal Hip Arthroplasty: A Risk-Adapted Three-Tier Model Based on a Large Patient Cohort. J Arthroplasty. 2026. PMID: 42705362. doi:10.1016/j.arth.2026.08.065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。